M. Phillip DeYoung - Concepedia

Author

M. Phillip DeYoung

Also Known As

M P DeYoung, M. P. DeYoung, M. Phillip DeYoung, M.P. Deyoung, M.Phillip DeYoung, M. Phillip Deyoung, Maurice Phillip DeYoung, Maurice Phillip Deyoung

122

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)Harvard University Massachusetts General Hospital Massachusetts Eye and Ear Infirmary Hospital Universitario Ramón y Cajal

About

M. Phillip DeYoung is an author at GlaxoSmithKline (United States) specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	905
2	Cell Biology	5	5	881
3	Pathology	3	3	470
4	Pharmacology	2	2	156
5	Cancer Cell Biology	1	1	132

M. Phillip DeYoung

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Hypoxia regulates TSC1/2–mTOR signaling and tumor suppression through REDD1-mediated 14–3–3 shuttling M. Phillip DeYoung, Peter Horak, Avi Sofer, Genes & Development	2008	688
p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis James W. Rocco, Chee‐Onn Leong, Nicolas Kuperwasser, Cancer Cell Tumor BiologyOncologySquamous Cell CarcinomaMedicineApoptosis	2006	421
The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers Chee‐Onn Leong, N. Vidnovic, M. Phillip DeYoung, Journal of Clinical Investigation	2007	267
Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis Peter Horak, Andrew Crawford, Douangsone D. Vadysirisack, Proceedings of the National Academy of Sciences Reductive StressCancer ResearchRadiation OncologySignal TransductionCell Regulation	2010	200
A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors Joaquı́n Mateo, Gopinath Ganji, Charlotte Lemech, Clinical Cancer Research	2017	138
Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1 Ayaz Najafov, Eeva Sommer, Jeffrey M. Axten, Biochemical Journal Specific InhibitorPdk1 TargetCancer BiologyTumor BiologyMolecular Pharmacology	2010	132
Tumor-Specific p73 Up-regulation Mediates p63 Dependence in Squamous Cell Carcinoma M. Phillip DeYoung, Cory M. Johannessen, Chee‐Onn Leong, Cancer Research Tumor BiologyPrimary KeratinocytesCell RegulationSquamous Cell CarcinomaRna Interference	2006	103
Long-Range Inhibitor-Induced Conformational Regulation of Human IRE1α Endoribonuclease Activity N.O. Concha, Angela Smallwood, William G. Bonnette, Molecular Pharmacology	2015	53
Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230 Christina Blackwell, Christian Sherk, Maggie Fricko, Oncotarget	2016	39
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma Emilie M.J. van Brummelen, E. Levchenko, Manuel Dómine, Investigational New Drugs Phase Ib StudyMalignant Pleural MesotheliomaPathologyFibroblast Growth FactorCancer Treatment	2019	25

Page 1